Ambroxol Hydrochloride for Injection

Pharmacology: This product has the characteristics of promoting mucus elimination and dissolving secretions. It can promote the elimination of viscous secretions in the respiratory tract and reduce the retention of mucus, thus significantly promoting expectoration and improving respiratory conditions. When using this product, the patient's mucus secretion can be restored to normal, cough and sputum volume are usually significantly reduced, and the surfactant of the mucosa on the respiratory tract can thus play its normal protective function. In the acute toxicity test of toxicology, LD50: 300 mg/kg for oral administration to mice; 140 mg/kg for intravenous injection, the toxicity index of ambroxol is very low. Ambroxol is non-mutagenic (Ames and micronucleus test). Carcinogenicity studies on mice and rats show that ambroxol is non-carcinogenic.

Trans-4-[(2-amino-3,5-dibromobenzylamino]cyclohexanol hydrochloride

This product is white or off-white loose lumps.

It is suitable for acute and chronic respiratory diseases accompanied by abnormal sputum secretion and poor sputum removal function, such as acute exacerbation of chronic bronchitis, asthmatic bronchitis, bronchiectasis and bronchial asthma. It is also suitable for the preventive treatment of postoperative pulmonary complications. It is also suitable for the treatment of premature infants and neonates with infant respiratory distress syndrome (IRDS).

Each 15 mg of this product is dissolved in 5 ml of sterile water for injection and slowly injected intravenously; it can also be mixed with glucose, fructose, 0.9% sodium chloride injection or Ringer's solution for intravenous drip. This product should not be mixed with alkaline solutions. In solutions with a pH greater than 6.3, it may cause precipitation of ambroxol free base. Preventive treatment Adults and children over 12 years old: 2-3 times a day, 15 mg each time; in severe cases, it can be increased to 30 mg each time Children 6-12 years old: 2-3 times a day, 15 mg each time Children 2-6 years old: 3 times a day, 7.5 mg each time Children under 2 years old: 2 times a day, 7.5 mg each time All are slowly injected intravenously. Infant breathing

This product is usually well tolerated. Mild gastrointestinal adverse reactions have been reported, mainly heartburn, indigestion, and occasional nausea and vomiting. Allergic reactions rarely occur, mainly rash. Severe acute allergic reactions have occurred in rare cases, but their relevance to ambroxol hydrochloride is not certain. Such patients are usually allergic to other substances. Rapid intravenous injection can cause headache, leg pain and fatigue.

The pH of this product after dissolving in sterile water for injection is 5.0. It cannot be mixed with other solutions with a pH greater than 6.3, because the increase in pH will lead to the precipitation of ambroxol free base.

The combined treatment of this product with antibiotics (amoxicillin, cefuroxime, erythromycin, doxycycline) can lead to increased concentrations of antibiotics in lung tissue. No clinically relevant adverse effects caused by combined use of this product with other drugs have been reported.

Keep in a dark and airtight container in a cool and dry place.

15mg

Hainan Weikang Pharmaceutical(Qianshan) Co., Ltd.

• Founded in:

  2002-07-10

• Address:

  No. 0008, Danxia Road, Qianshan Economic Development Zone, Anqing City, Anhui Province

• Tax NO.:

  913408247408673638

• Registered Funds:

  200 million yuan

• Website:

  Log in to view

• Email:

  Log in to view